Selinexor
Selinexor has been studied in 4 papers since 2025: none in people yet, 2 in animals, 2 in cells; 3 in the past year. The research so far is in animals and cells. The newest paper, Nov 3, 2026: “Selinexor, a CRM1 inhibitor with anti-senescence activity, modulates the non- coding transcriptome of Hutchinson–Gilford progeria syndrome fibroblasts”.
1 new paper in 30 daysSee all 4 papers on selinexor
At a glance
The findings reach mice, none yet in people. 2 independent labs in 2 countries; 167 trials, none about aging, 28 with no results posted.
None of its findings points the other way.
- 2 independent labs in 2 countries
- 167 trials, none about aging, 28 with no results posted
- Funders: Karyopharm Therapeutics and others
- 3 of 8 findings with company ties
- 9 of 167 trials sponsored by its developers
- Animals2
- Cells2
What did studies of selinexor find?
7Studies of selinexor measured 7 outcomes, among them autophagy, long noncoding RNA expression dysregulation and Progerin degradation.
Autophagy
upin human cells2
2 studies
Autophagy
upin human cells2
Selinexor activates autophagy in HGPS fibroblasts.
“treatment of HGPS fibroblasts with Selinexor, an autophagy activator, elicited nuclear accumulation of TFEB and enhanced lysosomal biogenesis and function, thereby activating autophagy”
Cellsin HGPS fibroblasts
Aging cell
Selinexor activates autophagy in HGPS fibroblasts.
“treatment of HGPS fibroblasts with selinexor mitigated senescence and promoted progerin clearance via autophagy”
Cellsin HGPS fibroblasts
Targeting CRM1 for Progeria Syndrome Therapy
Aging cell
Long noncoding RNA expression dysregulation
downin human cells1
1 study
Long noncoding RNA expression dysregulation
downin human cells1
Selinexor decreases long noncoding RNA expression dysregulation in human cells (Hutchinson-Gilford progeria syndrome).
“HGPS fibroblasts treated with selinexor, a CRM1-mediated nuclear export inhibitor with antisenescence activity, reversed missregulation of the lncRNA profile.”
CellsHutchinson-Gilford progeria syndromefibroblast
Research SquarePreprint
Progerin degradation
upin human cells1
1 study
Progerin degradation
upin human cells1
Selinexor increases progerin degradation in HGPS fibroblasts.
“Selinexor treatment improved both autophagosome maturation and autophagosome-lysosome fusion, which ultimately led to effective autophagic degradation of progerin”
Cellsin HGPS fibroblasts
Aging cell
age-associated inflammation
downin animals1
1 study
age-associated inflammation
downin animals1
Selinexor decreases age-associated inflammation.
“Inhibition of XPO1 with KPT-330 suppresses nuclear R-loop export and its localization into CCFs, attenuates the SASP, mitigates age-associated inflammation and extends healthspan.”
Animals
Nature aging
Senescence-associated secretory phenotype (SASP)
downin cells1
1 study
Senescence-associated secretory phenotype (SASP)
downin cells1
Selinexor decreases senescence-associated secretory phenotype (SASP) in cells.
“Inhibition of XPO1 with KPT-330 suppresses nuclear R-loop export and its localization into CCFs, attenuates the SASP”
Cells
Nature aging
Aortic histopathology
downin mice1
1 study
Aortic histopathology
downin mice1
Selinexor decreases aortic histopathology in LmnaG609G/G609G mice.
“oral administration of selinexor to the progeric mouse resulted in decreased progerin immunostaining in the liver and aorta, decreased progerin levels in most liver, lung and kidney samples analyzed by immunoblotting, and improved aortic histopathology”
Animalsin LmnaG609G/G609G miceaorta
Targeting CRM1 for Progeria Syndrome Therapy
Aging cell
Cellular senescence
downin human cells1
1 study
Cellular senescence
downin human cells1
Selinexor decreases cellular senescence in HGPS fibroblasts.
“treatment of HGPS fibroblasts with selinexor mitigated senescence and promoted progerin clearance via autophagy”
Cellsin HGPS fibroblasts
Targeting CRM1 for Progeria Syndrome Therapy
Aging cell
Has selinexor been tested in people?
0 of 167 about aging167 trials are registered, but no study of it in people has been published yet.
Approved
Jul 3, 2019Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
Mar 26, 2021Multiple Myeloma
Repurposing
Phase 3Completed2 trials
Phase 3Completed3 trials
Phase 3Active, not recruiting1 trial
Phase 3Completed1 trial
Phase 3Active, not recruiting5 trials
Phase 3Completed4 trials
40 of 62Fewer
In trials
Lymphoma, large b-cell, diffuse
Phase 4Status unknown10 trials
Leukemia myeloid acute
Phase 3Status unknown22 trials
Neoplasm by site
Phase 3Completed1 trial
Uterine disease
Phase 3Completed1 trial
Lymphoma t cell peripheral
Phase 2Terminated4 trials
Triple negative breast neoplasm
Phase 2Results posted3 trials
All 30Fewer
Readouts due
- Dec 2026
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2Active, not recruiting
- Dec 2026
- Apr 2027
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Phase 1/2Recruiting
- Apr 1, 2027
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Phase 1Recruiting
- May 1, 2027
- Jun 2027
All 9Fewer
Stopped
NCT01986348TerminatedGlioblastoma
Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2 patients were in survival follow-up)
NCT04843579TerminatedPlasma cell neoplasm
low enrollment
NCT04854434TerminatedColorectal neoplasm
Sponsor decision
NCT02314247TerminatedLymphoma t cell peripheral
Due to enrollment challenges
NCT04768881TerminatedMelanoma
The trial was terminated due to a lack of sufficient anti-melanoma tumor signal for the combination of selinexor + pembrolizumab.
NCT02213133TerminatedCarcinoma
Due to enrollment challenges and availability of other options for lung cancer patients. The termination is not a consequence of any safety concern.
All 14Fewer
Who is developing selinexor?
3 companies: Karyopharm Therapeutics, Qilu Pharmaceutical and US Oncology Research.
Trial sponsors
Company27 trialsPhase 34,682 people
Company4 trialsPhase 3350 people
Company1 trialPhase 3421 people
Company1 trialPhase 3228 people
Company1 trialPhase 3228 people
Company1 trialPhase 273 people
Company2 trialsPhase 152 people
Chongqing University Cancer Hospital
1 trialPhase 432 people